Response to blinatumomab
| . | Value, n (%) . |
|---|---|
| Response with blinatumomab in R/R B-cell ALL (N = 227) | |
| CR + CRi | 149 (67) |
| CR with MRD− | 109 (49) |
| CR with MRD+ | 37 (17) |
| CRi | 3 (1) |
| Partial remission | 8 (4) |
| Nonevaluable | 4 (2) |
| CR + CRi in Ph+ (n = 55) | 41 (74.5) |
| CR + CRi in primary refractory (n = 55) | 35 (64) |
| CR + CRi after salvage 1 (n = 126) | 90 (71) |
| CR + CRi after salvage 2 (n = 51) | 33 (65) |
| CR + CRi after early relapse (<18 months of first remission) (n = 121) | 78 (64) |
| CR + CRi after late relapse (≥36 months of first remission) (n = 17) | 12 (71) |
| Response to EMD (n = 10) | 2 (20) |
| Response with blinatumomab in B-cell ALL with MRD (n = 12) | |
| No. of patients who achieved MRD− | 9 (75) |
| . | Value, n (%) . |
|---|---|
| Response with blinatumomab in R/R B-cell ALL (N = 227) | |
| CR + CRi | 149 (67) |
| CR with MRD− | 109 (49) |
| CR with MRD+ | 37 (17) |
| CRi | 3 (1) |
| Partial remission | 8 (4) |
| Nonevaluable | 4 (2) |
| CR + CRi in Ph+ (n = 55) | 41 (74.5) |
| CR + CRi in primary refractory (n = 55) | 35 (64) |
| CR + CRi after salvage 1 (n = 126) | 90 (71) |
| CR + CRi after salvage 2 (n = 51) | 33 (65) |
| CR + CRi after early relapse (<18 months of first remission) (n = 121) | 78 (64) |
| CR + CRi after late relapse (≥36 months of first remission) (n = 17) | 12 (71) |
| Response to EMD (n = 10) | 2 (20) |
| Response with blinatumomab in B-cell ALL with MRD (n = 12) | |
| No. of patients who achieved MRD− | 9 (75) |